Skip to main content
  • SpePharm Sells Japanese Rights for Savene® to Kissei Pharmaceutical

    September 1, 2011

Amsterdam, 1st September 2011 – SpePharm Holding B.V.(Amsterdam, The Netherlands), the pan-European specialty pharmaceutical company, today announced that it has sold the Japanese rights to Savene® to Kissei Pharmaceutical Co. Ltd. (Matsumoto City, Nagano, Japan). As part of the transaction, SpePharm will also supply Savene® to Kissei Pharmaceutical for development and sale in Japan. Additional terms of the agreement are undisclosed.

In March 2010, SpePharm acquired worldwide rights (with the exception of North and South America) to Savene® from TopoTarget A/S (Copenhagen, Denmark). Savene® has been marketed in the EU since its approval by the EMA in July 2006 and is the only approved product for the treatment of extravasations, or leakage out of the blood stream, of certain commonly used anti-cancer drugs known as anthracyclines. If not adequately and timely treated, such extravasations can give rise to severe medical complications, including delays in cancer treatment and tissue necrosis that may require surgery or amputation.